OpGen (LTS:0A8L) Tax Provision : $0.00 Mil (TTM As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is OpGen Tax Provision?

OpGen's tax provision for the three months ended in Sep. 2023 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.

OpGen Tax Provision Historical Data

The historical data trend for OpGen's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OpGen Tax Provision Chart

OpGen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Tax Provision

Get a 7-Day Free Trial

-0.13

-0.04

OpGen Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Tax Provision	Get a 7-Day Free Trial															-	-	-	-	-

OpGen Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

OpGen (LTS:0A8L) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OpGen Inc (LTS:0A8L) » Definitions » Tax Provision

Comparable Companies

Traded in Other Exchanges

OPGN:USA 650:Germany

Address

9717 Key West Avenue, Suite 100, Rockville, MD, USA, 20850

Website

https://www.opgen.com

OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base.

OpGen (LTS:0A8L) Headlines

No Headlines